🟢 Milestone Pharmaceuticals is trading 6.25% up today with no confirmed catalyst explaining the move

Milestone Pharmaceuticals is trading 6.25% higher at $1.10, with no confirmed company-specific catalyst identified.

• The latest official release, dated August 21, announced initiation of a pivotal Phase 3 trial for etripamil in AFib-RVR.
• Available information does not directly connect that announcement to the current gain.
• Broader markets are modestly higher, without a sufficiently strong confirmed catalyst.